BioBusiness

A disciplined approach to changing behavior can achieve change agility.

The government of Turkey is drawing up a program in coordination with the pharmaceutical industry to create ways to make the country a regional production center for pharmaceuticals serving Europe, Central Asia, and the Middle East.

India has enforced stricter patent laws compared to other countries. For a drug to be patentable in India, the invention has to be novel, inventive, and industrially applicable.

Recently published research demonstrates how nanoparticles can be used to overcome hurdles in localized drug delivery.

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

Working together affords many unseen opportunities for pharmaceutical innovation.

Using a competency-based approach to effectively train biopharmaceutical industry staff.

NIH has awarded ten laboratories two-year grants to develop tissue chip technology, with part of the funding coming from the recently established National Center for Advancing Translational Science.

Brazil's regulatory health authority, Anvisa, plans to establish quality requirements for locally produced pharmaceutical excipients, Anvisa told BioPharm International.

After a series of government reforms, the Japanese pharma market is making a comeback.

A team from Northwestern University has demonstrated the feasibility of topical delivery of small interfering RNA (siRNA).

Now that the Supreme Court has upheld the Affordable Care Act, what's next for biopharma?

Steven S. Kuwahara, PhD, principal consultant at GXP BioTechnology LLC, gives an update on "Engineering the Cell-System Interface."

Collaborative R&D models coincide with new ways to fund translational research.

Selection of the right cell line, culture medium, and bioreactor conditions is key to setting up the upstream portion of the biopharmaceutical manufacturing process.

BIO is calling for a more patient-centric approach to user-fee reauthorization.

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.

The contract provider needs to know as much as the NDA holder.

Mike Clayman, CEO of Flexion Therapeutics, talks about his company's strategy to focus on a single therapeutic area.

A review of key industry shifts and promises for the future.

Formulators and developers are at the heart of the industry's basic premise-they are saving lives.

Industry experts discuss significant achievements. Plus: What's in store for the future.

Service providers must focus on delivering a superior customer experience.

This month, we rewind to an article titled "The Biotechnology Industry: A First Quarter Snapshot."

Future sponsor-contract provider relationships will require more integration.